Tight Regulation of Erk Activity Protects From Anthracycline-Induced Cardiotoxicity
Benedetta Coppe, Nadia Mercader · 2025
Read Tight Regulation of Erk Activity Protects From Anthracycline-Induced Cardiotoxicity by Benedetta Coppe, Nadia Mercader (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12805388.txt.
Description
Benedetta Coppe and Nadia Mercader wrote a 2025 commentary on a study that may point to a new shield against heart damage from cancer drugs. A class of cancer drugs called anthracyclines can harm the heart over time. They are used for leukemia, lymphoma, sarcoma, and breast cancer, so the risk touches many patients.
The harm builds through several paths, from damage to heart DNA to cell death and faster aging of the heart. Only one drug is approved to prevent it, so new options are needed. The study under review found that blocking a signal protein called Erk may protect the heart. Work in zebrafish, a common lab model for heart research, supports the lead. The commentary weighs what the finding could mean for safer cancer care.
Catalog record
| CREATOR | Benedetta Coppe, Nadia Mercader |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |